Immune checkpoint blockers and ovarian cancer [PDF]
Indian Journal of Medical and Paediatric Oncology, 2017 Although the idea, called “cancer immunotherapy,” is very appealing and has previously been shown to work in several mouse models of cancer, it has in general been very difficult to translate cancer immunotherapy approaches to humans.
Chinmoy K Bose
doaj +6 more sources
Biomarkers for immune checkpoint blockers [PDF]
HemaSphere, 2018 Kirsty Wienand, Margaret A. Shipp
doaj +4 more sources
Toward Systems Biomarkers of Response to Immune Checkpoint Blockers [PDF]
Frontiers in Oncology, 2020 Immunotherapy with checkpoint blockers (ICBs), aimed at unleashing the immune response toward tumor cells, has shown a great improvement in overall patient survival compared to standard therapy, but only in a subset of patients.
Óscar Lapuente-Santana +2 more
doaj +5 more sources
Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers [PDF]
Exploration of Targeted Anti-tumor Therapy, 2022 In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant.
Shiu Ying Tsao
doaj +4 more sources
Alleviation of exhaustion-induced immunosuppression and sepsis by immune checkpoint blockers sequentially administered with antibiotics—analysis of a new mathematical model [PDF]
Intensive Care Medicine Experimental, 2019 Background Sepsis-associated immune dysregulation, involving hyper-inflammation and immunosuppression, is common in intensive care patients, often leading to multiple organ dysfunction and death.
Avi Gillis +5 more
doaj +4 more sources
Targeting the NLRP3 inflammasome abrogates cardiotoxicity of immune checkpoint blockers [PDF]
Journal for ImmunoTherapy of CancerBackground Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many malignant tumors. However, ICI-induced hyper-immune activation causes cardiotoxicity.
Ping Li +14 more
doaj +4 more sources
Trial watch: Immune checkpoint blockers for cancer therapy [PDF]
OncoImmunology, 2017 Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of an ever more diversified panel of oncological indications.
Claire Vanpouille-Box +12 more
doaj +5 more sources
Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects [PDF]
Journal for ImmunoTherapy of Cancer, 2020 Background Oxazaphosphorines (cyclophosphamide (CPA), ifosfamide (IFO)) are major alkylating agents of polychemotherapy protocols but limiting their toxicity and increasing their efficacy could be of major interest.
Mélanie Desbois +5 more
doaj +5 more sources
Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy [PDF]
Frontiers in Oncology, 2022 Mazdak Ganjalikhani-Hakemi +7 more
doaj +5 more sources
Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma [PDF]
Scientific Reports, 2018 DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a single therapy.
Alessandra Lopes +7 more
doaj +3 more sources